TY - JOUR
T1 - Meeting report
T2 - WHO consultation on malaria vaccine development, Geneva, 15–16 July 2019
AU - Vekemans, Johan
AU - Schellenberg, David
AU - Benns, Sarah
AU - O'Brien, Kate
AU - Alonso, Pedro
N1 - Funding Information:
The organisation of this consultation benefitted from financial support from USAID and BMGF. The funders played no other role relative to the content of the meeting and this manuscript.
Publisher Copyright:
© 2021
PY - 2021/5/21
Y1 - 2021/5/21
N2 - Considerable progress has been made in malaria control in the last two decades, but progress has stalled in the last few years. New tools are needed to achieve public health goals in malaria control and elimination. A first generation vaccine, RTS,S/AS01, is currently being evaluated as it undergoes pilot implementation through routine health systems in parts of three African countries. The development of this vaccine took over 30 years and has been full of uncertainties. Even now, important unknowns remain as to its future role in public health. Lessons need to be learnt for second generation and future vaccines, including how to facilitate early planning of investments, streamlining of development, regulatory and policy pathways. A number of candidate vaccines populate the current development pipeline, some of which have the potential to contribute to burden reduction if efficacy is confirmed in conditions of natural exposure, and if they are amenable to affordable supply and programmatic implementation. New, innovative technologies will be needed if future malaria vaccines are to overcome important scientific hurdles and induce durable, high level protection. WHO convened a stakeholder consultation on the status of malaria vaccine research and development to inform the recently reconstituted Malaria Vaccine Advisory Committee (MALVAC) which will assist WHO in updating its current guidance and recommendations about priorities and product preferences for malaria vaccines.
AB - Considerable progress has been made in malaria control in the last two decades, but progress has stalled in the last few years. New tools are needed to achieve public health goals in malaria control and elimination. A first generation vaccine, RTS,S/AS01, is currently being evaluated as it undergoes pilot implementation through routine health systems in parts of three African countries. The development of this vaccine took over 30 years and has been full of uncertainties. Even now, important unknowns remain as to its future role in public health. Lessons need to be learnt for second generation and future vaccines, including how to facilitate early planning of investments, streamlining of development, regulatory and policy pathways. A number of candidate vaccines populate the current development pipeline, some of which have the potential to contribute to burden reduction if efficacy is confirmed in conditions of natural exposure, and if they are amenable to affordable supply and programmatic implementation. New, innovative technologies will be needed if future malaria vaccines are to overcome important scientific hurdles and induce durable, high level protection. WHO convened a stakeholder consultation on the status of malaria vaccine research and development to inform the recently reconstituted Malaria Vaccine Advisory Committee (MALVAC) which will assist WHO in updating its current guidance and recommendations about priorities and product preferences for malaria vaccines.
KW - Africa
KW - Malaria
KW - Plasmodium falciparum
KW - Plasmodium vivax
KW - Vaccines
KW - World Health Organization
UR - http://www.scopus.com/inward/record.url?scp=85107088542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107088542&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.03.093
DO - 10.1016/j.vaccine.2021.03.093
M3 - Article
C2 - 33931251
AN - SCOPUS:85107088542
SN - 0264-410X
VL - 39
SP - 2907
EP - 2916
JO - Vaccine
JF - Vaccine
IS - 22
ER -